Caribou Biosciences, Inc. (CRBU) News
Filter CRBU News Items
CRBU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRBU News Highlights
- For CRBU, its 30 day story count is now at 5.
- Over the past 7 days, the trend for CRBU's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- GENE, ARM and CB are the most mentioned tickers in articles about CRBU.
Latest CRBU News From Around the Web
Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.
3 Gene-Editing Stocks With the Potential to Mint MillionairesGene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. |
5 Things to Know Before The Stock Market OpensThe Federal Reserve will conclude its last policy meeting of the year with a decision to hold interest rates steady expected, and Tesla issued a recall over its Autopilot drive-assistance system. Here’s what investors need to know today. |
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 -- -- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 -- BERKELEY, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharma |
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Next-Gen Biotech: 3 Companies Leading the Charge in Gene TherapyThese three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. |
Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to TradeThe mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 285.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 321.5% in Caribou Biosciences, Inc. (CRBU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Subdued Growth No Barrier To Caribou Biosciences, Inc. (NASDAQ:CRBU) With Shares Advancing 28%Those holding Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares would be relieved that the share price has rebounded 28... |
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients -- -- CB-012 AMpLify Phase 1 trial site activation underway following recent IND clearance; expect to initiate enrollment by mid-2024 in r/r AML patients -- -- $396.7 million in cash, cash equivalents, and marketable securities e |
Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue EstimatesEntrada Therapeutics, Inc. (TRDA) delivered earnings and revenue surprises of 285.45% and 168.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |